EPCAM and neoplasm: The oncolytic group B adenovirus EnAdenotucirev (EnAdV) was modified by Freedman and colleagues to express another BiTE coordinately binding EpCAM+ tumor cells and CD3+ T cells, leading to clustering and activation of both CD4+ and CD8+ T cells with tumor cells [73].